This article is more than 5 years old. Information may no longer be current.

Triamcinolone after pars plana vitrectomy for diabetic hemorrhage reduces rebleeding, reoperation

Retina. 2008;28(9):1241-1246.

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Intravitreal injection of triamcinolone acetonide at the end of pars plana vitrectomy for diabetic vitreous hemorrhage may help prevent early rebleeding and reoperation.

After surgery, 38 patients receiving a 4-mg injection of triamcinolone had significantly greater visual acuity at 6 months (0.63 ± 0.23 logMAR) when compared with 34 postoperative patients who did not receive the injection (0.87 ± 0.24 logMAR; P < .001).

At day 1 and week 1 after surgery, mean IOP was higher in the triamcinolone group compared with control eyes, but IOP did not differ at 1, 3 or 6 months postoperatively. There was cataract progression in both groups, but there was no difference in the rate of progression when patients who were not dosed at the end of surgery were compared with patients who were dosed.

However, the researchers noted, patients who received triamcinolone during surgery had a higher risk of posterior capsular progression compared with patients who did not receive an injection (P = .011).